PMID- 36094043
OWN - NLM
STAT- MEDLINE
DCOM- 20221011
LR  - 20230912
IS  - 1531-7021 (Electronic)
IS  - 1040-8738 (Linking)
VI  - 33
IP  - 6
DP  - 2022 Nov 1
TI  - Treatment of metastatic uveal melanoma in 2022: improved treatment regimens and 
      improved prognosis.
PG  - 585-590
LID - 10.1097/ICU.0000000000000905 [doi]
AB  - PURPOSE OF REVIEW: Until recently, metastatic uveal melanoma was associated with 
      essentially uniform fatality within months. However, recent developments in 
      screening, improved understanding of the genetic underpinnings of metastatic 
      disease, and pivotal medication approvals have improved the disease's rate of 
      fatality. RECENT FINDINGS: Routine implementation of genetic testing at the time 
      of primary tumor treatment via gene expression profiling or chromosomal analysis 
      has identified patients who are at high risk for metastatic disease. Enhanced 
      screening with imaging directed at the liver and lungs has allowed for 
      identification of early disease and lower tumor burden. Significant work on 
      improved liver directed therapy along with systemic chemotherapy and 
      immunotherapy has improved life expectancy. The first systemic immunotherapy 
      specifically for metastatic uveal melanoma was approved this year. This 
      medication, tebentafusp, is likely to improve life expectancy for all patients 
      with metastatic melanoma assuming they have appropriate human leukocyte antigen 
      (HLA) markers. Multiple clinical trials with novel immunotherapeutic agents are 
      promising as well. SUMMARY: The prognosis for patients with uveal melanoma is far 
      better than ever before because of recent developments in the understanding and 
      treatment of metastatic disease.
CI  - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Reichstein, David
AU  - Reichstein D
AD  - Tennessee Retina, PC.
FAU - Brock, Anderson
AU  - Brock A
AD  - Tennessee Retina, PC.
FAU - Lietman, Caressa
AU  - Lietman C
AD  - Sarah Cannon Cancer Research Institute, Nashville, Tennessee, USA.
FAU - McKean, Meredith
AU  - McKean M
AD  - Sarah Cannon Cancer Research Institute, Nashville, Tennessee, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220908
PL  - United States
TA  - Curr Opin Ophthalmol
JT  - Current opinion in ophthalmology
JID - 9011108
RN  - 0 (Recombinant Fusion Proteins)
RN  - N658GY6L3E (tebentafusp)
RN  - Uveal melanoma
SB  - IM
MH  - Humans
MH  - *Melanoma/genetics/therapy
MH  - Prognosis
MH  - Recombinant Fusion Proteins
MH  - *Uveal Neoplasms/genetics
EDAT- 2022/09/13 06:00
MHDA- 2022/10/12 06:00
CRDT- 2022/09/12 07:33
PHST- 2022/09/13 06:00 [pubmed]
PHST- 2022/10/12 06:00 [medline]
PHST- 2022/09/12 07:33 [entrez]
AID - 00055735-202211000-00018 [pii]
AID - 10.1097/ICU.0000000000000905 [doi]
PST - ppublish
SO  - Curr Opin Ophthalmol. 2022 Nov 1;33(6):585-590. doi: 
      10.1097/ICU.0000000000000905. Epub 2022 Sep 8.